HC Wainwright Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $25.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective lowered by HC Wainwright from $50.00 to $25.00 in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. Wedbush cut their price target on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Cantor Fitzgerald boosted their price objective on shares of Ultragenyx Pharmaceutical from $96.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Robert W. Baird cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $40.00 to $16.00 in a report on Thursday. Finally, Evercore downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target for the company. in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $36.63.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $15.30 on Thursday. The stock’s 50 day moving average price is $27.76 and its 200 day moving average price is $24.97. Ultragenyx Pharmaceutical has a 1-year low of $13.81 and a 1-year high of $39.89. The company has a market cap of $1.51 billion, a PE ratio of -2.62 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The firm had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. During the same quarter in the prior year, the business posted ($1.17) earnings per share. Ultragenyx Pharmaceutical’s revenue was up 28.5% compared to the same quarter last year. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical will post -3.98 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, EVP Karah Parschauer sold 1,899 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president directly owned 94,462 shares in the company, valued at $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Corsee Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the transaction, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently made changes to their positions in the stock. Versant Capital Management Inc increased its position in Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,001 shares in the last quarter. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $39,000. Quantbot Technologies LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $48,000. Harbor Investment Advisory LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $52,000. Finally, Parallel Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
• Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
• Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
• Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
• Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
• Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.